ArticleFrontiers in endocrinology2026
Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a growing public health concern associated with increased risk of chronic diseases, including type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become a key therapeutic option for obesity management, yet real-world evidence describing short-term changes in body composition, particularly with newer agents such as tirzepatide, remains limited. This retrospective study examined changes in body weight, body mass index (BMI), and body composition among adults with obesity receiving GLP-1 receptor agonist therapy within a clinical obesity medicine program that included individualized lifestyle guidance. Thirty-five adults (53.4 ± 7.8 years; BMI 37.2 ± 9.16 kg/m²) receiving tirzepatide were evaluated. Therapy was initiated at 2.5 mg or 5 mg once weekly, with scaffolded dose escalation up to 15 mg based on tolerance and clinical response. Body weight was measured using standard procedures, and body composition was assessed with bioelectrical impedance analysis (InBody770) at baseline and follow-up visits. Linear mixed models and ANOVA were used to examine effects of time, sex, and baseline weight status (p < 0.050).GLP-1RA therapy resulted in significant reductions in body weight (-31.1 kg; -27.8%), BMI (-10.4 kg/m²; -27.8%), body fat percentage (-16.2%; -37.6%), fat mass (-26.4 kg; -54.2%), fat-free mass (-4.5 kg; -7.3%), skeletal muscle mass (-2.8 kg; -8.3%), and total body water (-3.5 kg; -7.7%) (all p < 0.001). Weight loss was predominantly attributable to fat mass, comprising 85.7% (95% CI: 81.9, 89.5) of total weight loss, with smaller contributions from fat-free and skeletal muscle mass. Reductions in extracellular (-2.6 kg; -9.5%) and intracellular water (-1.3 kg; -7.4%) were observed; however, fluid distribution indices did not change significantly over time.Sex-specific analyses showed females experienced greater percentage reductions in fat mass, fat-free mass, skeletal muscle mass, and total body water compared to males, while males exhibited greater reductions in fluid ratios (p < 0.05). Participants with higher baseline BMI demonstrated significantly greater percentage reductions in weight, BMI, fat mass, and body fat percentage compared to those with lower baseline BMI (p < 0.05), although post-treatment values were not significantly different between groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.